You are here

Article Text

Article menu

Download PDFPDF

Letters
PostScript
Aminoglycoside ototoxicity susceptibility in cystic fibrosis
Free
  1. S A Mulrennan,
  2. J Helm,
  3. R Bright Thomas,
  4. M Dodd,
  5. A Jones,
  6. K Webb
  1. Adult Cystic Fibrosis Unit, Wythenshawe Hospital, Manchester, UK
  1. Professor K Webb, Adult Cystic Fibrosis Unit, Wythenshawe Hospital, Manchester M23 9LT, UK; the5webbs{at}hotmail.com

https://doi.org/10.1136/thx.2008.103010

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Ototoxicity is a recognised dose-related complication of aminoglycoside antibiotics.

    Predisposition to these ototoxic effects, even when levels are within the therapeutic range, is associated with an inherited mitochondrial DNA mutation known as m.1555A>G.1 2

    We report a case of a 22-year-old woman with cystic fibrosis (CF), genotype delta F508 homozygous, with bilateral high frequency hearing loss. This was discovered when an audiogram (not previously performed) was requested for routine screening by our centre before commencement of nebulised TOBI (preservative-free pH-adjusted preparation of tobramycin for inhalation).

    She had a history of diabetes mellitus, exocrine pancreatic insufficiency and developed chronic Pseudomonas aeruginosa infection when aged 5 …

    View Full Text